FLT3 and acute myeloid leukemia: Furthermore, inhibitors with activity against both Fes and Flt3-ITD kinases in vitro blocked Flt3-ITD+ AML cell growth in the low to mid-nanomolar range, suggesting that dual inhibition of this key AML driver mutation and the proximal effector kinase Fes may provide added benefit in this type of AML.